Ignite Creation Date:
2024-05-06 @ 2:51 AM
Last Modification Date:
2024-10-26 @ 11:24 AM
Study NCT ID:
NCT02145143
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-18
First Post:
2014-05-20
Brief Title:
Enhancing Radioiodine RAI Incorporation Into BRAF Mutant RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib A Pilot Study
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Enhancing Radioiodine RAI Incorporation Into BRAF Mutant RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib A Pilot Study
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out what effects good andor bad a drug called vemurafenib either alone or combined with another treatment called radioactive iodine has on the patient and thyroid cancer It is not known if vemurafenib works against thyroid cancer This study will test in a small number of patients if it can be used with radioactive iodine to treat thyroid cancers This type of study is called a pilot study If the results are positive a larger study with more patients may be done to further test this treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None